ecteinascidin 743 has been researched along with Local Neoplasm Recurrence in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (7.94) | 29.6817 |
| 2010's | 45 (71.43) | 24.3611 |
| 2020's | 13 (20.63) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, S; Bessede, A; Blay, JY; Brahmi, M; Chakiba, C; Cousin, S; Croce, S; Floquet, A; Giraud, A; Guégan, JP; Italiano, A; Kind, M; Mathoulin-Pelissier, S; Perret, R; Pulido, M; Ray-Coquard, I; Toulmonde, M; Toulza, E | 1 |
| Alvarez-Breckenridge, CA; Brastianos, PK; Cahill, DP | 1 |
| Coukos, G; Digklia, A; Homicsko, K | 1 |
| Grignani, G; Hindi, N; Ibrahim, T; Le Cesne, A; Martín-Broto, J; Merlini, A | 1 |
| Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F | 1 |
| Avesani, G; Boccia, SM; Corrado, G; Fagotti, A; Marchetti, C; Scambia, G; Tiberi, G; Vertechy, L | 1 |
| Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P | 1 |
| Keung, EZ; Nassif, EF; Somaiah, N; Thirasastr, P | 1 |
| Alvarez, R; Blay, JY; Casali, PG; Cruz Jurado, J; Dei Tos, AP; Fabbroni, C; Gronchi, A; Gutierrez, A; Hindi, N; Italiano, A; Lopez-Pousa, A; Martin-Broto, J; Morosi, C; Pérez Aguiar, JL; Ranchere-Vince, D; Rincón-Perez, I; Romagosa, C; Romero, J; Sanfilippo, R; Sangalli, C; Sunyach, MP | 1 |
| Barra, F; Bifulco, G; D'Alessandro, G; Della Corte, L; Evangelisti, G; Ferrero, S; Stigliani, S; Tantari, M | 1 |
| Bourgeois, H; Brusa, F; Casado, A; De Rivas, B; de Sande, LM; Dopchie, C; Ibarbia, MA; Naglieri, E; Pignata, S; Reichert, D; Scambia, G; Sorio, R; Villanucci, A | 1 |
| González-Martín, A; Lorusso, D; Ray-Coquard, I | 1 |
| Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M | 1 |
| Amadio, G; de Vincenzo, R; Distefano, M; Ferrandina, G; Palluzzi, E; Paris, I; Ricci, C; Scambia, G | 1 |
| Adam, JP; Boumedien, F; Letarte, N; Provencher, D | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Bonetti, A; Giuliani, J | 1 |
| C Cecere, S; Du Bois, A; Harter, P; Heitz, F; Pignata, S | 1 |
| Arenare, L; Califano, D; Cecere, SC; Di Napoli, M; Losito, NS; Orditura, M; Paciolla, I; Pignata, S; Pisano, C; Setola, SV; Ventriglia, J | 1 |
| Dry, SM; Eilber, FC; Elliott, I; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Singh, SR; Tome, Y | 1 |
| Colombo, N | 1 |
| Ray-Coquard, I | 1 |
| Marth, C | 1 |
| Alonso, T; Cabezas, S; Callata, HR; Casado, A; Díaz-Rubio, E; Fernández, C; Gajate, P; Manzano, A; Marquina, G; Sotelo, M | 1 |
| Amano, K; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Ito, T; Kumagai, Y; Mochiki, E; Muramatsu, S; Muta, Y; Suzuki, O; Toyomasu, Y | 1 |
| Arcusa, Á; Barretina-Ginesta, P; Bover, I; Casado, A; Del Campo, JM; García, Y; González-Martín, A; González-Santiago, S; Guerra, E; Herrero, A; Mallol, P; Martín, L; Martínez, A; Mori, M; Ortega, E; Romero, I; Rubio, MJ; Santaballa, A; Vicente, D; Vidal, L | 1 |
| Ahrens, M; Bauer, S; Grabellus, F; Hoiczyk, M; Podleska, L; Pöttgen, C; Schuler, M; Schwindenhammer, B; Taeger, G | 1 |
| Fisher, M; Gore, M | 1 |
| Aracil, M; Badri, N; Galmarini, CM; Herzog, TJ; Kaye, SB; Monk, BJ; Nieto, A; Parekh, TV; Poveda, A; Tanović, A | 1 |
| Colombo, N; Lopez-Guerrero, JA; Poveda, A; Ray-Coquard, I; Romero, I | 1 |
| Bazaeva, IIa; Cherkasova, MV; Gorbunova, VA; Khokhlova, SV; Limareva, SV; Orel, NF | 1 |
| Baracos, VE; Birdsell, L; Parekh, T; Park, YC; Prado, CM; Sawyer, MB; Stuyckens, K; Xiao, J | 1 |
| De Sarro, G; Di Paola, ED; Gallelli, L; Leporini, C; Lucia, M; Patanè, M; Rende, P; Rossi, M; Russo, E; Saullo, F; Toscano, R | 1 |
| López-Guerrero, JA; Poveda, A; Romero, I | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Cheng, PS; Favis, R; Ghatage, P; Henitz, E; Knoblauch, R; Li, W; Matos-Pita, AS; Monk, BJ; Nieto, A; Parekh, T; Park, YC; Poveda, A; Ricci, D | 1 |
| Bosacki, C; Espenel, S; Jacquin, JP; Magné, N; Méry, B; Moriceau, G; Pacaut, C; Rivoirard, R; Trone, JC; Vallard, A | 1 |
| Abdul Razak, AR; Angarita, FA; Blackstein, ME; Cannell, AJ; Dickson, BC | 1 |
| Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH | 1 |
| Colombo, N; Ferrandina, G; Hardy-Bessard, AC; Marth, C; Romero, I | 1 |
| du Bois, A; González-Martín, A | 1 |
| Herzog, TJ; Teplinsky, E | 1 |
| Bayever, E; Braly, P; Crispens, M; Doering, D; Lisyanskaya, A; Markman, M; McMeekin, DS; Michiels, B; Oza, AM | 1 |
| Bidzinski, M; Boman, K; Ciuleanu, TE; Del Campo, JM; Hogberg, T; Lebedinsky, C; Poveda, A; Roszak, A; Westermann, AM; Wojtukiewicz, MZ | 1 |
| Carter, NJ; Keam, SJ | 1 |
| Bidzinski, M; Ghatage, P; Gorbounova, VA; Herzog, TJ; Kaye, SB; Krasner, CN; Lebedinsky, CA; Lisyanskaya, AS; Makhson, AN; Monk, BJ; Muggia, FM; Nam, JH; Ngan, HY; Park, YC; Poveda, AM; Pujade-Lauraine, E; Rolski, J; Shen, K; Vergote, IB; Vermorken, JB | 1 |
| Cannistra, SA | 1 |
| Del Campo, JM; Diaz de Corcuera, I; Muñoz-Couselo, E; Oaknin, A | 1 |
| Cantos, B; López-González, A; Provencio, M; Tejerina, E | 1 |
| D'Incalci, M; Sessa, C | 1 |
| Bonebrake, AJ; De Geest, K; Edwards, R; Hanjani, P; Monk, BJ; Rotmensch, J; Sill, MW; Walker, JL | 1 |
| Evans, P; Papaioannou, D; Rafia, R; Stevens, JW; Stevenson, MD | 1 |
| Markman, M | 1 |
| Kaye, SB; Lebedinsky, CA; McCormack, R; Monk, BJ; Parekh, T; Poveda, A; Ricci, D; Tercero, JC; Wang, S; Zintl, P | 1 |
| Alfaro, V; González-Martín, A; Sehouli, J | 1 |
| Blessing, JA; Burke, JJ; Hensley, ML; Monk, BJ; Muller, CY; Street, DG | 1 |
| Herzog, TJ; Kaye, SB; Krasner, CN; Monk, BJ; Muggia, FM; Parekh, TV; Park, YC; Poveda, AM; Pujade-Lauraine, E; Vermorken, JB | 1 |
| Aikin, A; Balis, FM; Bayever, E; Chuk, MK; Fox, E; Whitcomb, T; Widemann, BC; Zannikos, P | 1 |
| Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
| Colombo, N; del Campo, JM; Gómez, J; Gore, M; Kaye, S; Krasner, CN; McMeekin, S; Parekh, T; Park, YC; Sessa, C; Vermorken, JB; Zintl, P | 1 |
| Burton, A | 1 |
| Cowan, C; Koontz, MZ; Monk, BJ; Saffari, B; Tewari, D; Wallick, AC | 1 |
| Braly, PS; Campos, S; Chan, S; Gore, ME; Kaye, S; Krasner, CN; McMeekin, DS; Provencher, DM; Renshaw, FG | 1 |
18 review(s) available for ecteinascidin 743 and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Myxoid Liposarcomas: Systemic Treatment Options.
Topics: Adult; Anthracyclines; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Progression-Free Survival; Trabectedin | 2023 |
Treatment of recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin in Ovarian Cancer: is it now a Standard of Care?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Standard of Care; Trabectedin | 2018 |
Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Trabectedin | 2018 |
Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Practice Guidelines as Topic; Tetrahydroisoquinolines; Trabectedin | 2014 |
[Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Patient Selection; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug Interactions; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2014 |
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Dioxoles; DNA Damage; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Major clinical research advances in gynecologic cancer in 2015.
Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms | 2016 |
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Hypersensitivity; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making; Dioxoles; Doxorubicin; Female; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
The efficacy of trabectedin in treating ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Discovery; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2017 |
Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Tetrahydroisoquinolines; Trabectedin | 2010 |
Trabectedin for the treatment of relapsed ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Doxorubicin; Female; Humans; Mesalamine; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Randomized Controlled Trials as Topic; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2012 |
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Vomiting | 2013 |
17 trial(s) available for ecteinascidin 743 and Local Neoplasm Recurrence
| Article | Year |
|---|---|
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin | 2023 |
A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Trabectedin | 2021 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Decision Support Techniques; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Models, Theoretical; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Tetrahydroisoquinolines; Trabectedin; United Kingdom | 2013 |
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
Topics: Biomarkers; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nuclear Proteins; Ovarian Neoplasms; Polyethylene Glycols; Proportional Hazards Models; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Body Composition; Dexamethasone; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome | 2014 |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Dioxoles; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenetics; Polyethylene Glycols; Tetrahydroisoquinolines; Time Factors; Trabectedin; Transcription Factors; Treatment Outcome | 2015 |
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2009 |
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Stomatitis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2011 |
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2011 |
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2012 |
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Survival Analysis; Tetrahydroisoquinolines; Trabectedin | 2012 |
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Child; Dexamethasone; Dioxoles; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Recurrence; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2012 |
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
Topics: Adolescent; Adult; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2007 |
28 other study(ies) available for ecteinascidin 743 and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
Topics: Antibodies, Monoclonal; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Trabectedin for recurrent WHO grade 2 or 3 meningiomas-Paving the road for new opportunities.
Topics: Brain Neoplasms; Humans; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Local; Trabectedin; World Health Organization | 2022 |
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Experience with second-line trabectedin in daily clinical practice: case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Liposarcoma; Male; Neoplasm Recurrence, Local; Quality of Life; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2022 |
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Case-Control Studies; Disease Progression; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Trabectedin | 2023 |
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Trabectedin for the therapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2020 |
Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Trabectedin | 2021 |
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult | 2021 |
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Italy; Neoplasm Recurrence, Local; Oncologists; Ovarian Neoplasms; Polyethylene Glycols; Practice Patterns, Physicians'; Surveys and Questionnaires; Tetrahydroisoquinolines; Trabectedin | 2017 |
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma; Dioxoles; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Humans; Liposarcoma; Male; Mice; Neoplasm Recurrence, Local; Receptor, Platelet-Derived Growth Factor alpha; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2018 |
Management of relapsed ovarian cancer in routine clinical practice: a case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Care Team; Platinum Compounds; Polyethylene Glycols; Trabectedin; Treatment Outcome | 2018 |
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Trabectedin; Treatment Outcome | 2018 |
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Trabectedin | 2019 |
[A Case of Giant Retroperitoneal Liposarcoma Resected after Trabectedin Chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retroperitoneal Neoplasms; Trabectedin | 2018 |
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Trabectedin | 2019 |
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Dioxoles; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Activity of trabectidin in desmoplastic small round cell tumor.
Topics: Adolescent; Desmoplastic Small Round Cell Tumor; Dioxoles; Humans; Male; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin in ovarian cancer: could we expect more?
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
Topics: Adenocarcinoma, Clear Cell; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dioxoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Lymphatic Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Tetrahydroisoquinolines; Trabectedin | 2013 |
Sea squirt assaults sarcomas.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2002 |
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Drugs, Investigational; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2006 |